Deal Library / Pharma BD Deal Intelligence

Johnson & Johnson — Pharma Deals

The Pharma Closeout tracks 27 deals, $167.3B in disclosed deal value, 22 with a post-close Outcome Score for Johnson & Johnson.

Median Critic Score: 75  ·  Median Outcome Score: 71

Best outcome: Johnson & Johnson / Centocor Inc. (92)  ·  Weakest outcome: Johnson & Johnson / Animas Corporation (23)

All 27 deals

• Johnson & Johnson / Centocor Inc. — 1999 · $4.9B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Cougar Biotechnology, Inc. — 2009 · $970M · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Actelion Ltd — 2017 · $30.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Aragon Pharmaceuticals Inc. — 2013 · $1.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Legend Biotech Corporation — 2017 · $350M · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Synthes Inc. — 2011 · $19.7B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Intra-Cellular Therapies — 2025 · $14.6B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Shockwave Medical — 2024 · $13.1B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Crucell NV — 2003 · $2.4B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Abiomed Inc. — 2022 · $16.6B · Largely worked — most objectives met.
• Johnson & Johnson / Momenta Pharmaceuticals Inc. — 2020 · $6.5B · Largely worked — most objectives met.
• Johnson & Johnson / Abbott Medical Optics — 2003 · $4.3B · Largely worked — most objectives met.
• Johnson & Johnson / ALZA Corporation — 2001 · $10.5B · Largely worked — most objectives met.
• Johnson & Johnson / Proteologix Inc. — 2024 · $850M · Largely worked — most objectives met.
• Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) — 2016 · $4.3B · Largely worked — most objectives met.
• Johnson & Johnson / Firefly Bio, Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Ambrx Biopharma Inc. — 2024 · $2.0B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Pfizer Consumer Healthcare — 2006 · $16.6B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Neutrogena — 1994 · $924M · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Crucell N.V. — 2010 · $2.4B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / TransForm Pharmaceuticals, Inc. — 2005 · $230M · Underwhelmed — fell short of the thesis.
• Johnson & Johnson / Animas Corporation — 2005 · $518M · Did not work — the deal failed to deliver.
• Johnson & Johnson / Halda Therapeutics, Inc. — 2025 · $3.0B
• Johnson & Johnson / Numab Therapeutics AG (Yellow Jersey Therapeutics) — 2024 · $1.2B
• Johnson & Johnson / Fate Therapeutics, Inc. — 2020 · $3.1B
• Johnson & Johnson / Auris Health, Inc. — 2019 · $5.8B
• Johnson & Johnson / Tibotec-Virco NV — 2002 · $320M

← Deal Library  ·  Interactive search  ·  How we score deals